Zhu covers the Healthcare sector, focusing on stocks such as Revolution Medicines, IDEAYA Biosciences, and Kura Oncology. According to TipRanks, Zhu has an average return of 19.4% and a 52.80% success rate on recommended stocks.
In addition to LifeSci Capital, Nuvalent also received a Hold from Wells Fargo’s Eva Fortea Verdejo in a report issued on June 10. However, on June 2, H.C. Wainwright maintained a Buy rating on Nuvalent (NASDAQ: NUVL).
Based on Nuvalent’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $109.28 million. In comparison, last year the company had a GAAP net loss of $84.58 million
